Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus versus mycophenolate sodium after lung transplantation for prevention of bronchiolitis obliterans syndrome
2004-001290-25Phase 3Completed
- Sponsor
- St Vincent's Hospital
- Start
- Aug 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, mycophenolate sodium, cyclosporine and corticosteroids in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by St Vincent's Hospital. Primary endpoint: Development of bronchiolitis obliterans syndrome. Started Aug 2005; status: completed.
02
Drugs
everolimusmycophenolate sodiumcyclosporinecorticosteroids
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2004-001290-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001290-25.